HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

torbafylline

structure given in first source

Also Known As:

7-(ethoxymethyl)-3,7-dihydro-1-(5-hydroxy-5-methylhexyl)-3-methyl-1-H-purine-2,6-dione; HWA 448; HWA-448

Networked: 13 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purinones: 2
        Xanthines: 123
        Theobromine: 130
        Pentoxifylline: 2585
        torbafylline: 13

Experts

1.	Balasubramaniam, Ambikaipakan: 1 article (08/2014)
2.	Friend, Lou Ann: 1 article (08/2014)
3.	James, J Howard: 1 article (08/2014)
4.	Joshi, Rashika: 1 article (08/2014)
5.	Kadeer, Nijiati: 1 article (08/2014)
6.	Sheriff, Sulaiman: 1 article (08/2014)
7.	Attaix, Didier: 1 article (01/2002)
8.	Claustre, Agnès: 1 article (01/2002)
9.	Combaret, Lydie: 1 article (01/2002)
10.	Obled, Christiane: 1 article (01/2002)

Related Diseases

1.	Fatigue 07/01/1994 - "Some of the deleterious effects on ischemic muscles of strenuous activity (reduced blood flow during contractions, less resistance to fatigue) were remedied by torbafylline treatment, and values normalized. " 07/04/1989 - "Three weeks oral treatment with torbafylline (25 mg/kg per day) decreased fatigue to 68%. " 07/01/1994 - "Torbafylline treatment had little further effect on ischemic muscles subjected to mild stimulation, which on its own improved functional hyperemia, resistance to fatigue, and the capillaries per fibre ratio in tibialis anterior, although it did significantly increase the capillary per fibre ratio in extensor digitorum longus. "
2.	Muscular Diseases (Myopathy) 08/01/1993 - "Torbafylline might thus prove effective in stimulating muscle regeneration in myopathy."
3.	Hyperemia 07/01/1994 - "Torbafylline treatment had little further effect on ischemic muscles subjected to mild stimulation, which on its own improved functional hyperemia, resistance to fatigue, and the capillaries per fibre ratio in tibialis anterior, although it did significantly increase the capillary per fibre ratio in extensor digitorum longus. "
4.	Neoplasms (Cancer) 01/15/2002 - "Taken together, the data indicate that HWA 448 is a powerful inhibitor of muscle wasting that blocks enhanced Ub-proteasome-dependent proteolysis in situations where TNF production rises, including cancer and sepsis." 11/01/1998 - "The aim of this study was to quantify and compare the effects of three methylxanthine derivatives: pentoxifylline (PX), torbafylline (TB), and HWA 138 (HW) on tumor perfusion and oxygenation. " 01/15/2002 - "Torbafylline (HWA 448) inhibits enhanced skeletal muscle ubiquitin-proteasome-dependent proteolysis in cancer and septic rats." 03/01/1997 - "Torbafylline, a xanthine derivative which inhibits tumor necrosis factor production, prevented the activation of protein breakdown and the increased expression of 20S proteasome subunits in cancer rats, without reducing the elevated MSS1 mRNA levels. "
5.	Candidiasis (Moniliasis) 01/01/1991 - "The present study investigated a dose-dependent protection of a structurally similar methylxanthine, HWA-448, in the candidiasis rat model given a single dose of AmpB. "

Related Drugs and Biologics

1.	methylxanthine
2.	Pentoxifylline (Trental)
3.	1- (5- hydroxy- 5- methylhexyl)- 3- methylxanthine
4.	torbafylline
5.	Proteasome Endopeptidase Complex (Proteasome)
6.	Ubiquitin
7.	Xanthine
8.	Messenger RNA (mRNA)
9.	Proteins (Proteins, Gene)
10.	Interleukin-6 (Interleukin 6)

Related Therapies and Procedures

1.	Exercise Therapy (Therapy, Exercise)